OMS721 for Patients with IgAN
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
This Phase 3 study will determine is OMS721 is safe and effective at reducing symptoms for patients with IgAN.
Trial for people with
To determine if OMS721 reduces proteinuria in patients with IgAN.
What is involved for the Patient?
Patients will be involved with the trial for about 2 years, and will take either the study medication or the placebo.
About the drug or intervention
MASP-2, is a novel pro-inflammatory protein target involved in activation of the complement system, which is an important component of the immune system.
- Study CoordinatorLaura Haas
- Study Coordinator Emaillhaas@omeros.com
- Study Coordinator Phone(206) 676-0886
- SponsorOmeros Corporation
- Study DrugOMS721
- Estimated enrollment430
- Estimated end dateApril 2023